Spain Vs Italy 20 players confirmed for Spain's Euro 2024 squad, and three po...
Current status of ARBs in BD.ppt
1. ARBs
(Angiotensin II Receptor Blockers)
Presented by
Mohammed Moshiur Rahaman
Brand Executive
Brand Management Department
Strategic Brand Management Division
The ACME Laboratories Ltd.
2. Indications
Main Indication :
For the treatment of hypertension
Other Indications :
1. Diabetic nephropathy (kidney damage due
to diabetes)
2. Congestive heart failure
3. Available ARBs In World
Losartan
Candesartan
Valsartan
Irbesartan
Telmesartan
Eprosartan
Olmesartan (FDA 2002)
Azilsartan (FDA 2011)
5. Azilsartan
Olmesartan
Valsatan
Losartan
Generic
Azilsartan Medoxomil INN
Olmesartan Medoxomil USP
Valsartan INN
Losartan Potassium USP
Therapeutic Class
Antihypertensive (ARBs)
Antihypertensive (ARBs)
Antihypertensive (ARBs)
Antihypertensive (ARBs)
Dosage Form
Tablet
Tablet
Tablet
Tablet
Strength
40 mg & 80 mg
10 mg, 20 mg & 40 mg
40 mg, 80 mg & 160 mg
25 mg, 50 mg & 100 mg
Drug Interactions
No significant drug-drug
interactions
No significant drug-drug
interactions
No significant drug-drug
interactions
No significant drug-drug
interactions
Pregnancy category
D
C
C
C
Use in children
Safety and effectiveness
have not been established
Safety and effectiveness
have been established
Safety and effectiveness
have not been established
Safety and effectiveness
have been established
FDA/BNF approval
FDA approved (2011)
FDA approved (2002)
FDA approved (2001)
FDA approved (1995)
Pharmacokinetic data
Bioavailability: 60%
Half-life: 11 hours
Bioavailability: 29%
Half-life: 13 hours
Bioavailability: 25%
Half-life: 6 hours
Bioavailability: 33%
Half-life: 6-9 hours
AT1 affinity
More than 10000 fold
12500 fold
20000 fold
10000 fold
tmax (h)
1.5-3.0 hrs
1.4-2.8 hrs
2 hrs
3-4 hrs
6. Clinical Trails
Azilsartan at its maximal dose has superior
efficacy to both Olmesartan and Valsartan at
their maximal, approved doses without increasing
adverse events. Azilsartan could provide higher
rates of hypertension controls within the ARB
class.
Ref: Hypertension, 2011 Mar, 57 (3): 413-420. Epub 2011 Jan 31
(Pubmed)
